APA (7th ed.) Citation

L, P., FS, M., T, L., E, P., E, M., WC, C., . . . MB, T. (2026). Immunogenicity and safety of MVA-BN vaccine administered 5 years after a two-dose primary series in DR Congo: A prospective cohort study. The Lancet. Infectious diseases, 26(6), 571. https://doi.org/10.1016/S1473-3099(26)00001-0

Chicago Style (17th ed.) Citation

L, Priyamvada, et al. "Immunogenicity and Safety of MVA-BN Vaccine Administered 5 Years After a Two-dose Primary Series in DR Congo: A Prospective Cohort Study." The Lancet. Infectious Diseases 26, no. 6 (2026): 571. https://doi.org/10.1016/S1473-3099(26)00001-0.

MLA (9th ed.) Citation

L, Priyamvada, et al. "Immunogenicity and Safety of MVA-BN Vaccine Administered 5 Years After a Two-dose Primary Series in DR Congo: A Prospective Cohort Study." The Lancet. Infectious Diseases, vol. 26, no. 6, 2026, p. 571, https://doi.org/10.1016/S1473-3099(26)00001-0.